Zafgen Inc (NASDAQ:ZFGN) – Equities researchers at Wedbush issued their FY2023 earnings per share estimates for Zafgen in a note issued to investors on Tuesday, March 12th. Wedbush analyst L. Moussatos anticipates that the biopharmaceutical company will earn ($1.55) per share for the year.
A number of other research analysts have also recently issued reports on the stock. JMP Securities lifted their price target on shares of Zafgen from $8.00 to $17.00 and gave the company a “hold” rating in a research report on Tuesday. They noted that the move was a valuation call. Piper Jaffray Companies cut their target price on shares of Zafgen from $18.00 to $6.00 and set a “hold” rating for the company in a research report on Monday. Zacks Investment Research downgraded shares of Zafgen from a “hold” rating to a “sell” rating in a report on Saturday, March 2nd. Svb Leerink raised shares of Zafgen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 7th. Finally, Leerink Swann raised shares of Zafgen from a “market perform” rating to an “outperform” rating and set a $4.52 target price on the stock in a report on Thursday, February 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $9.45.
NASDAQ:ZFGN opened at $3.03 on Thursday. Zafgen has a 12 month low of $2.78 and a 12 month high of $12.35. The company has a debt-to-equity ratio of 0.16, a current ratio of 11.78 and a quick ratio of 11.78. The stock has a market capitalization of $106.56 million, a PE ratio of -1.59 and a beta of -0.35.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.04.
Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in shares of Zafgen by 47.6% during the third quarter. BlackRock Inc. now owns 2,121,820 shares of the biopharmaceutical company’s stock valued at $24,805,000 after buying an additional 683,888 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Zafgen by 14.1% during the 3rd quarter. Vanguard Group Inc now owns 1,468,584 shares of the biopharmaceutical company’s stock worth $17,168,000 after purchasing an additional 181,396 shares during the period. Renaissance Technologies LLC grew its stake in shares of Zafgen by 18.6% during the 3rd quarter. Renaissance Technologies LLC now owns 770,300 shares of the biopharmaceutical company’s stock worth $9,005,000 after purchasing an additional 120,600 shares during the period. Algert Global LLC lifted its position in shares of Zafgen by 287.8% during the 3rd quarter. Algert Global LLC now owns 73,955 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 54,885 shares in the last quarter. Finally, First Manhattan Co. purchased a new position in shares of Zafgen during the 4th quarter valued at approximately $27,000. 86.09% of the stock is owned by institutional investors and hedge funds.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Recommended Story: What is Liquidity?
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.